GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » 3-Year EPS without NRI Growth Rate

JWCTF (JW (Cayman) Therapeutics Co) 3-Year EPS without NRI Growth Rate : 52.60% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co 3-Year EPS without NRI Growth Rate?

JW (Cayman) Therapeutics Co's EPS without NRI for the six months ended in Jun. 2024 was $-0.08.

During the past 3 years, the average EPS without NRI Growth Rate was 52.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of JW (Cayman) Therapeutics Co was 52.60% per year. The lowest was -68.40% per year. And the median was -32.70% per year.


Competitive Comparison of JW (Cayman) Therapeutics Co's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW (Cayman) Therapeutics Co's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's 3-Year EPS without NRI Growth Rate falls into.



JW (Cayman) Therapeutics Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


JW (Cayman) Therapeutics Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co Headlines

No Headlines